PharmiWeb.com - Global Pharma News & Resources
27-Feb-2021

Global Primary Hyperoxaluria Drug Market 2021 by Type, by Application and Region: Premium Insights, Key Players Review and COVID 19 Impact Analysis, 2015 – 2027

Global Primary Hyperoxaluria Drug Market 2021 by Type, by Application and Region: Premium Insights, Key Players Review and COVID 19 Impact Analysis, 2015 – 2027

Summary

Global Primary Hyperoxaluria Drug Market was valued at around USD 100 million in 2019 and expected to grow at a CAGR of over 7.25% to reach over USD 130 million in 2027.
Editor: Jay Turner Last Updated: 02-Mar-2021

Extreme urinary excretion of oxalate is termed as hyperoxaluria. Patients suffering from calcium oxalate kidney stones are often have hyperoxaluria. Generally, hyperoxaluria is inherited (genetic) disorder. Also, an intestinal disease or eating too many oxalate-rich foods can result into hyperoxaluria. Early detection and treatment of hyperoxaluria can prevent from any adverse effects on kidney. Global Primary Hyperoxaluria Drug Market was valued at around USD 100 million in 2019 and expected to grow at a CAGR of over 7.25% to reach over USD 130 million in 2027.

Primary hyperoxaluria drugs are predominantly used I n North America and Europe at present. However, with rising awareness and increased diagnostic facilities, demand for primary hyperoxaluria drugs is expected to be triggered in emerging economies such as China and India. High investment in research & development by leading industry participants is expected to open new growth window for them. With strong research and development initiative, most of the companies are focusing on innovative and cost-effective drug development.

Download FREE Sample PDF of Global Primary Hyperoxaluria Drug Market: https://www.eonmarketresearch.com/sample/76622

By type, global Primary Hyperoxaluria Drug market is segmented into ALLN-230, DCR-PHXC, ALN-GO1 and Others. ALLN-230 dominated the global primary hyperoxaluria drugs market with over 34% share in 2019. It is also expected to exhibit fastest CAGR during the forecast period.

Increasing prevalence is driving demand for primary hyperoxaluria drugs around the world. It is estimated to affect 1 in 58,000 individuals worldwide. Type 1 is the most common form, accounting for approximately 80 percent of cases. Types 2 and 3 each account for about 10 percent of cases. By application, global Primary Hyperoxaluria Drug market is segmented into Hospital, Clinic and Others. Hospitals segment dominated the global primary hyperoxaluria drug market with over 50% share in 2019. Demand for clinics is also expected to exhibit the fastest CAGR over the forecast period.

Global Primary Hyperoxaluria Drug market is dominated by the North America. North America accounted for over 50% share in 2019. Easy availability, higher penetration of drugs and higher level of heath awareness among end-users is driving the demand for primary hyperoxaluria drugs in the region. Europe was the second leading market for primary hyperoxaluria drugs. However, with increasing penetration and rising health awareness, Asia Pacific is expected to advance with fastest CAGR during the forecast period.

Customization of the Report: This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@eonmarketresearch.com), who will ensure that you get a report that suits your needs.

Major companies analyzed in the report include but not limited to Allena Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Intellia Therapeutics Inc, OxThera AB and Others. Global Primary Hyperoxaluria Drug market is moderately fragmented with few handfuls of large companies. Top five companies accounted for one third share in total revenue generated by this industry.

Segmentation:

Primary Hyperoxaluria Drug Market by Type, 2015 – 2027 Revenue (USD Million)

  • ALLN-230
  • DCR-PHXC
  • ALN-GO1
  • Others

Primary Hyperoxaluria Drug Market by Application, 2015 – 2027 Revenue (USD Million)

  • Hospitals
  • Clinics
  • Others

Buy This Premium Report: https://www.eonmarketresearch.com/buy/76622

Primary Hyperoxaluria Drug Market by Region, 2015 – 2027 Revenue (USD Million)

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • UK
  • Russia
  • Italy
  • Spain

Asia Pacific

  • China
  • Japan
  • South Korea
  • India
  • Southeast Asia
  • Australia

Latin America

  • Brazil
  • Argentina
  • Chile
  • Peru

Middle East and Africa

  • Egypt
  • Saudi Arabia
  • South Africa
  • Turkey
  • Israel

Primary Hyperoxaluria Drug Market by Company, 2018 – 2019 Revenue (USD Million)

  • Allena Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Dicerna Pharmaceuticals Inc
  • Intellia Therapeutics Inc
  • OxThera AB
  • Others

Do Inquiry Before Purchasing Report Here and Ask For Discount: https://www.eonmarketresearch.com/enquiry/76622

Explore Related Reports:

  1. Cerebroprotein Hydrolysate Market
  2. Caries Detection Devices Market
  3. Dental Fittings Market
  4. Pediatric Wheelchairs Market
  5. Exosome Diagnostics and Therapeutics Market

About Us:

Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.

Contact Us:

Eon Market Research

Phone: +1 703 879 7090

Email: sales@eonmarketresearch.com